|Yale University, M.D.|
Dr. Jay Kranzler was appointed Chief Executive Officer of Cypress in December 1995. During his tenure, Cypress has successfully raised $226 million in new funding, executed multiple license agreements, and gained FDA approval of two therapeutics, including the companyâ€™s lead product, SavellaTM (milnacipran HCl), for the management of fibromyalgia. Under Dr. Kranzlerâ€™s leadership, Cypress initiated research into this novel therapeutic area, which resulted in the licensing of the compound from Pierre Fabre, and advancing the U.S. development of Savella. In addition, Dr. Kranzler was instrumental in establishing a licensing and co-promotion agreement with Forest Laboratories in 2004, and in the acquisition of Proprius Pharmaceuticals in 2008, supporting Cypressâ€™ maturation to a uniquely positioned commercial enterprise.